ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Oct 25, 2021 19:00 JST
Source:
Genetec Technology Bhd
Genetec Q2FY2022 PAT Up by Sixfold
Company records strong Q2 performance of RM16.30 million, exceeding industry expectations
BANGI, Malaysia, Oct 25, 2021 - (ACN Newswire) - Genetec Technology Berhad ("Genetec" or the "Company"), a technology leader in providing customised full turnkey smart factory automation manufacturing lines, today announced that the Company recorded profit after tax ("PAT") of RM16.30 million for the second quarter ended 30 September 2021 ("Q2FY2022"), which is 515% higher than the PAT of RM2.65 million registered for the corresponding second quarter ended 30 September 2020 ("Q2FY2021").
Genetec also announced their proposal of a bonus issue of 661,564,800 new ordinary shares in Genetec ("Bonus Shares") on the basis of twelve (12) Bonus Shares for every one (1) existing ordinary share in Genetec ("Genetec Share" or "Share") held on an entitlement date to be determined later ("Proposed Bonus Issue"). The Entitlement Date will be determined and announced at a later date upon receipt of all relevant approvals for the Proposed Bonus Issue. In addition, for purposes of clarity, the actual number of Bonus Shares to be issued will depend on the total number of issued Shares on the Entitlement Date and is not intended to be implemented on a staggered basis. Further and final details will be announced upon receipt of all relevant approvals soon.
Genetec registered RM17.59 million in profit before tax ("PBT") for the quarter under review, which is 554% higher than the PBT of RM2.69 million recorded for Q2FY2021 while revenue of RM59.31 million is 53% higher than the RM38.67 million posted in Q2FY2021. Earnings per share stood at 31.25 sen (fully diluted) in Q2FY2022 compared to EPS of 6.18 sen in Q2FY2021.
For the first-half of the financial year ended 31 March 2022 ("1HFY2022"), the Company recorded 2884% higher PAT of RM24.50 million compared to the corresponding period of the previous financial year, when the Company posted PAT of RM821,000. PBT for 1HFY2022 stood at RM26.44 million, which is 2848% higher than the PBT of RM897,000 while revenue is 95% higher at RM99.59 million compared to RM51.10 million of the corresponding period of the previous financial year.
In their announcements the Company highlighted, "It has been an eventful year. Genetec's bonus issue proposal is part of our efforts to enhance trading liquidity of the Genetec shares, following the recent share price appreciation, as well as to reward existing shareholders on the back of the strong performance of the EV and energy storage divisions. The strong performances have contributed significantly to overall revenue amid steady demand for more sustainable modes of transport and energy. We expect the order book for the EV division to remain significant and to continue contributing to Genetec's financial performance in the coming quarters. As countries and companies step up their transition towards more sustainable and zero emission transport and energy solutions, we are confident that this growth trajectory will continue. It is well supported by the trifecta of global regulatory frameworks, new incentives to promote the adoption of EVs, and a fast-expanding range of EVs. Meanwhile, EV models are becoming more accessible as the ecosystem grows and battery costs drop further."
"While we have a more positive outlook as the global economy reopens amid higher vaccination rates, we remain cautious of spikes in COVID-19 infections that may result in supply-chain disruptions and affect consumer sentiment."
Source: Genetec Technology Bhd
Sectors: Daily Finance, Local Biz, Manufacturing
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Hong Kong Watch & Clock Fair, Salon de TIME return in September
Aug 30, 2025 14:00 JST
Honda Announces New Plan for Relocation of Global Head Office to Yaesu Area in Tokyo and Reconstruction of Honda Aoyama Building
Aug 29, 2025 18:54 JST
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 29, 2025 18:17 JST
Hitachi Energy acquires remaining stake of eks Energy, reinforcing leadership in power conversion systems for energy storage
Aug 29, 2025 15:17 JST
SenseTime Announces 2025 Interim Results
Aug 28, 2025 21:20 JST
Ausnutria 2025 Interim Results Announcement: Revenue and Profit Maintain Resilient Dual Growth
Aug 28, 2025 19:09 JST
Baguio Green Group (1397.HK) Announces 2025 Interim Results
Aug 28, 2025 19:03 JST
Production, Sales and Export Results for July, 2025
Aug 28, 2025 17:36 JST
Sales, Production, and Export Results for July 2025
Aug 28, 2025 17:25 JST
The University of Tokyo and DENSO Jointly Establish a Social Cooperation Program: "Building Sustainable Production System Infrastructure with Advanced AI Technology"
Aug 28, 2025 16:33 JST
Overview of Honda Exhibits at the Japan Mobility Show 2025
Aug 28, 2025 15:49 JST
NEC develops AI technology for digitalizing work tasks without the need for pre-training and utilizing video from multiple cameras covering wide area worksites
Aug 27, 2025 22:57 JST
Result of the Business Plan Review for the Offshore Wind Power Generation Projects in Japan
Aug 27, 2025 22:27 JST
Fujitsu develops AI agent platform for the healthcare sector to enhance operational efficiency and ensure stable medical service provision
Aug 27, 2025 21:50 JST
MHI Becomes First Japanese Company to Acquire ISO 19443:2018 Certification in the Nuclear Energy Field
Aug 27, 2025 21:32 JST
Mitsubishi Logisnext to Demonstrate Automated Forklift Equipped with "SynfoX" at "4th INNOVATION EXPO"
Aug 27, 2025 20:59 JST
TANAKA to Showcase Advanced Semiconductor Materials in its Inaugural Participation at SEMICON India 2025
Aug 26, 2025 13:30 JST
Honda to Hold Official e-Motorsports Event, "Honda Racing eMS 2025"
Aug 26, 2025 13:17 JST
Mitsubishi Corporation Invests in Fullerton Health
Aug 26, 2025 12:54 JST
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 25, 2025 19:30 JST
More Latest Release >>
Related Release
Genetec reinforces foundation for growth, maintains resilient outlook
August 29 2025 17:10 JST
Genetec maintains profitability in Q3FY2025 on higher revenue
May 29 2025 20:00 JST
Genetec maintains stable and profitable performance on a lower Q1FY2025 revenue
November 27 2024 10:00 JST
Genetec's Consistent Performance Delivers Higher Overall Margins in Q4FY2024
May 28 2024 19:18 JST
Genetec Sets the Stage for Higher Growth Following a Strong Q3FY2024 Performance
February 27 2024 20:00 JST
Genetec Powers ahead with Steady Growth in Q2FY2024
November 29 2023 17:00 JST
Genetec's Q2FY2023 Performance Remains on Track
November 29 2022 17:00 JST
Genetec's Quarterly Performance Jumps by 126%
August 29 2022 18:00 JST
Genetec Scales New Heights with Highest Annual Profit to Date
May 26 2022 18:00 JST
Genetec Delivers Its Best Quarter to Date
January 26 2022 16:00 JST
More Press release >>